1227 related articles for article (PubMed ID: 30697701)
1. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
5. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
[TBL] [Abstract][Full Text] [Related]
6. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Estcourt LJ; Malouf R; Trivella M; Fergusson DA; Hopewell S; Murphy MF
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011305. PubMed ID: 28128441
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Chakupurakal G; Freudenberger P; Skoetz N; Ahr H; Theurich S
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009159. PubMed ID: 37341189
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
[TBL] [Abstract][Full Text] [Related]
10. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
Zhao L; Chen S; Yang P; Cao H; Li L
Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
[TBL] [Abstract][Full Text] [Related]
11. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.
Cheuk DK; Chiang AK; Ha SY; Chan GC
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009311. PubMed ID: 26017019
[TBL] [Abstract][Full Text] [Related]
12. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L
Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242
[TBL] [Abstract][Full Text] [Related]
14. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Crighton GL; Estcourt LJ; Wood EM; Trivella M; Doree C; Stanworth S
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010981. PubMed ID: 26422767
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures.
Huber J; Stanworth SJ; Doree C; Fortin PM; Trivella M; Brunskill SJ; Hopewell S; Wilkinson KL; Estcourt LJ
Cochrane Database Syst Rev; 2019 Nov; 11(11):CD012745. PubMed ID: 31778223
[TBL] [Abstract][Full Text] [Related]
16. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A; Fraquelli M; Prati D; Casazza G
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013532. PubMed ID: 37278488
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
19. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]